Individualized management and therapy of myelodysplastic syndromes;Die individualisierte riskoeinschätzung und therapieplanung bei myelodysplastischen syndromen

Wiener Klinische Wochenschrift

Volumn 120, Issue 17-18, 2008, Pages 523-537

  Stauder, Reinhard ^a   Wimazal, Friedrich ^b   Nösslinger, Thomas ^c   Krieger, Otto ^d   Sperr, Wolfgang R ^b   Sill, Heinz ^e   Pfeilstöcker, Michael ^c   Valent, Peter ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c HANUSCH HOSPITAL   (Austria)

^d ELISABETHINEN HOSPITAL   (Austria)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMSACRINE; ANTHRACYCLINE; AZACITIDINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; CYTOSINE; DEFERASIROX; DEFEROXAMINE; ERYTHROPOIETIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; IDARUBICIN; LENALIDOMIDE; METHOTREXATE; THALIDOMIDE; THYMOCYTE ANTIBODY; TOPOTECAN; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUSTRIA; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CONSTIPATION; CYTOREDUCTIVE SURGERY; DISEASE COURSE; DRUG DOSE REDUCTION; FATIGUE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; IRON CHELATION; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; PARESTHESIA; PRIMARY TUMOR; PROGNOSIS; REVIEW; RISK ASSESSMENT; THERAPY EFFECT; THROMBOSIS;

ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; MYELODYSPLASTIC SYNDROMES; STEM CELL TRANSPLANTATION;

EID: 56049086984     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-008-1058-6     Document Type: Review

References (112)

1. WK Hofmann HP Koeffler 2005 Myelodysplastic syndrome Annu Rev Med 56 1 16
2. P Valent HP Horny JM Bennett C Fonatsch U Germing P Greenberg 2007 Definitions and standards in the diagnosis and treatment of myelodysplastic syndromes: consensus statements and report from a working conference Leukemia Research 31 6 727 736
3. JM Bennett D Catovsky MT Daniel G Flandrin DA Galton HR Gralnick 1982 Proposals for the classification of the myelodysplastic syndromes Br J Haematol 51 189 199
4. NL Harris ES Jaffe J Diebold G Flandrin HK Muller-Hermelink J Vardiman 1997 World Health Organization of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting. Airlie House, Virginia J Clin Oncol 17 3835 3849
5. U Germing C Strupp A Kündgen D Bowen C Aul R Haas 2004 No increase in age-specific incidence of myelodysplastic syndromes Haematologica 89 8 905 910
6. Rocco G, Oberaigner W, Gastl G, Fiegl M, Stauder R (2003) Myelodysplastic syndrome and acute myeloid leukemia in Tyrol: incidence and distribution. Onkologie [Suppl 5]: 23, S121, #P683
7. P Greenberg C Cox MM LeBeau P Fenaux P Morel G Sanz 1997 International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 2079 2088
8. C Aul N Gattermann A Heyll U Germing G Derigs W Schneider 1992 Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system Leukemia 6 1 52 59
9. U Germing B Hildebrandt M Pfeilstöcker T Nösslinger P Valent C Fonatsch 2005 Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS) Leukemia 19 2223 2231
10. ML Sorror MB Maris R Storb F Baron BM Sandmaier DG Maloney 2005 Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT Blood 106 8 2912 2919
11. R Stauder 2007 Why is comorbidity so relevant in MDS patients? The MDS News - The Newsletter of the Myelodysplastic Syndromes Foundation 12 1 1 3
12. Stauder R, Noesslinger T, Pfeilstöcker M, Sperr WR, Wimazal F, Krieger O, et al (2008) Impact of age and comorbidity in myelodysplastic syndromes. JNCCN (in press)
13. L Malcovati MG Della Porta M Cazzola 2006 Predicting survival and leukemic evolution in patients with myelodysplastic syndrome Haematologica 91 12 1588 1590
14. L Malcovati U Germing A Kuendgen MG Della Porta C Pascutto R Invernizzi 2007 Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes J Clin Oncol 25 23 3503 3510
15. Statistik Austria. www.statistik.at
16. Nösslinger T, Tüchler H, Germing U, Sperr WR, Krieger O, Haase D, et al. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes (Submitted)
17. ME Charlson P Pompei KL Ales CR MacKenzie 1987 A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 5 373 383
18. ML Sorror MB Maris 2004 Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning: influence of pretransplant comorbidities Blood 104 4 961 968
19. Haase D, U. Germing, J. Schanz, M. Pfeilstöcker, T. Nösslinger, B. Hildebrandt, et al (2007) Comprehensive cytogenetics of MDS: correlations with morphology and delineation of new prognostic markers in 2124 patients. Blood, Aug 28
20. Steidl C, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Kündgen A, et al (2008) Growing evidence for an underestimation of poor risk cytogenetics in the international prognostic scoring system in myelodysplastic syndromes. Clinical Leukemia (in press)
21. C Gardin P Fenaux 2004 Supportive care including growth factors in myelodysplastic syndromes Rev Clin Exp Hematol 8 2 E3
22. EP Alessandrino S Amadori G Barosi M Cazzola A Grossi LN Liberato 2002 Italian society of hematology. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology Haematologica 87 12 1286 1306
23. D Bowen D Culligan S Jowitt S Kelsey G Mufti D Oscier 2003 UK MDS Guidelines Group. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes Br J Haematol 120 2 187 200
24. A Greinacher V Kiefel H Klüter H Kroll B Pötzsch H Riess 2006 Recommendations for platelet transfusion by the Joint Thrombocyte Working Party of the German Societies of Transfusion Medicine and Immunohaematology (DGTI), Thrombosis and Haemostasis Research (GTH), and Haematology and Oncology (DGHO) Dtsch Med Wochenschr 131 47 2675 2679
25. EORTC Guidelines 2006. Eur J Cancer 42: 2433-2453
26. ASCO Guidelines 2006. J Clin Onc 24: 3187-3205
27. National Comprehensive Cancer Network® Guidelines. www.nccn.org/professionals/physician_gls/PDF/mds.pdf
28. E Hellström-Lindberg L Malcovati 2008 Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes Semin Hematol 45 1 14 22
29. M Nairz G Weiss 2006 Molecular and clinical aspects of iron homeostasis: from anemia to hemochromatosis Wien Klin Wochenschr 118 15-16 442 462
30. SS Bottomley 1998 Secondary iron overload disorders Sem Hematol 35 77 86
31. J Varkonyi J Demeter A Tordai H Andrikovics 2006 The significance of the hemochromatosis genetic variants in multiple myeloma in comparison to that of myelodysplastic syndrome Ann Hematol 85 869 871
32. AI Schafer RG Cheron R Dluhy B Cooper RE Gleason JS Soeldner 1981 Clinical consequences of acquired transfusional iron overload in adults N Engl J Med 304 319 324
33. L Malcovati 2007 Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes Leuk Res 31 Suppl 3 S2 S6
34. GM Brittenham PM Griffith AW Nienhuis CE McLaren NS Young EE Tucker 1994 N Engl J Med 331 567 573
35. HA Leitch TA Goodman KK Wong LM Vickars PF Galbraith CS Leger 2006 Improved survival in patients with myelodysplastic syndrome (MDS) receiving iron chelation therapy Blood 108 11 78a
36. C Rose S Brechignac D Vassilief O Beyne-Rauzy A Stamatoullas D Larbaa 2007 Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM Blood 110 11 80a 81a
37. N Gattermann J Porter LF Lopes J Seymour 2005 Consensus Statement on iron overload in myelodysplastic syndromes Hematol Oncol Clin North Am 19 Suppl 1 18 25
38. P Valent O Krieger R Stauder F Wimazal T Nösslinger WR Sperr 2008 Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform Eur J Clin Invest 38 3 143 149
39. TG St Pierre PR Clark W Chua Ansorn AJ Fleming GP Jeffrey JK Olnyk 2005 Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance Blood 105 855 861
40. M Hussain D Flynn N Green S Hussein A Hoffbrand 1976 Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload Lancet 2 1278 1280
41. AR Cohen R Galanello A Piga V De Sanctis F Tricta 2003 Safety and effectiveness of long term therapy with the oral iron chelator deferiprone Blood 102 1583 1587
42. J Porter R Galanello G Saglio EJ Neufeld E Vichinsky MD Cappellini 2008 Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study Eur J Haematol 80 2 168 176
43. M Cappellini A Cohen A Piga M Bejaoui S Perrotta L Agaoglu 2006 A phase III study of deferasirox (ICL670) a once daily oral iron chelator in patients with β thalassemia Blood 107 3455 3462
44. E Hellstrom-Lindberg R Negrin R Stein S Krantz G Lindberg J Vardiman 1997 Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model Br J Haematol 99 2 344 351
45. E Hellstrom-Lindberg N Gulbrandsen G Lindberg T Ahlgren IM Dahl I Dybedal 2003 Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life Br J Haematol 120 6 1037 1046
46. N Casadevall P Durieux S Dubois F Hemery E Lepage MC Quarré 2004 Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial Blood 104 2 321 327
47. JD Rizzo MR Somerfield KL Hagerty J Seidenfeld J Bohlius CL Bennett 2008 Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update Blood 111 25 41
48. R Stasi E Abruzzese G Lanzetta E Terzoli S. Amadori 2005 Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes Ann Oncol 16 12 1921 1927
49. L Mannone C Gardin MC Quarre JF Bernard D Vassilieff L Ades Groupe Francais des Myelodysplasies 2006 High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study Br J Haematol 133 5 351 335
50. P Giraldo B Nomdedeu J Loscertales C Requena R de Paz M Tormo 2006 Aranesp in Myelodysplastic Syndromes (ARM) Study Group. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes Cancer 107 12 2807 2816
51. SD Ross IE Allen CA Probst B Sercus SM Crean G Ranganathan 2007 Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis Oncologist 12 10 1264 1273
52. Moyo V, Lefebvre P, Duh MS, Yektashenas B, Mundle S. (2008) Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol 20
53. JF Patton T Sullivan Y Mun T Reeves G Rossi JF Wallace 2005 A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome J Support Oncol 3 6 419 426 Erratum in: J Support Oncol (2006) 4 (3): 107
54. R Stasi A Pagano E Terzoli S Amadori 1999 Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes Br J Haematol 105 1 141 148
55. JB Bartlett K Dredge AG Dalgleish 2004 The evolution of thalidomide and its IMiD derivatives as anticancer agents Nat Rev Cancer 4 4 314 322
56. P Musto 2004 Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Review Leuk Res 28 4 325 332
57. R Invernizzi E Travaglino M De Amici S Brugnatelli I Ramajoli B Rovati 2005 Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes Leuk Res 29 6 641 647
58. A List S Kurtin DJ Roe A Buresh D Mahadevan D Fuchs 2005 Efficacy of lenalidomide in myelodysplastic syndromes N Engl J Med 352 6 549 557
59. A List G Dewald J Bennett A Giagounidis A Raza E Feldman 2006 Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion N Engl J Med 355 14 1456 1465
60. A Raza JA Reeves EJ Feldman GW Dewald JM Bennett HJ Deeg 2008 Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q Blood 111 1 86 93
61. A Giagounidis P Fenaux GJ Mufti P Muus U Platzbecker G Sanz 2008 Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes Ann Hematol 87 5 345 352
62. Giagounidis A, Haase S, Platzbecker U, Germing U, Lohrbacher V, Ehninger G, et al (2007) Risk factors for disease progression in del(5q) MDS patients treated with lenalidomide. Abstract. Blood #1460
63. A Tichelli A Gratwohl A Wuersch C Nissen B Speck 1988 Antilymphocyte globulin for myelodysplastic syndrome Br J Haematol 68 1 139 140
64. JJ Molldrem E Leifer E Bahceci Y Saunthararajah M Rivera C Dunbar 2002 Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes Ann Intern Med 137 3 156 163
65. JJ Molldrem M Caples D Mavroudis M Plante NS Young AJ Barrett 1997 Antithymocyte globulin for patients with myelodysplastic syndrome Br J Haematol 99 3 699 705
66. Y Saunthararajah R Nakamura R Wesley QJ Wang AJ Barrett 2003 A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome Blood 102 8 3025 3027
67. Claus R, Ruter B, Lubbert M (2007) Targets of epigenetic therapy - Gene reactivation as a novel approach in MDS treatment. Cancer Treat Rev, pp 47-52
68. PM Das R Singal 2004 DNA methylation and cancer J Clin Oncol 22 22 4632
69. Garcia-Manero G (2007) Modifying the epigenome as a therapeutic strategy in myelodysplasia. Hematology Am Soc Hematol Educ Program, pp 405-411
70. A Kuendgen M Lübbert 2008 Current status of epigenetic treatment in myelodysplastic syndromes Ann Hematol 87 8 601 611
71. LR Silverman EP Demakos BL Peterson AB Kornblith JC Holland R Odchimar-Reissig 2002 Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B J Clin Oncol 20 10 2429 2440
72. LR Silverman DR McKenzie BL Peterson JF Holland JT Backstrom CL Beach 2006 Cancer and Leukemia Group B. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B J Clin Oncol 24 24 3895 3903
73. Fenaux P, Mufti GJ, Santini V, Finelli C, Giagounidis A, Schoch R, et al (2007) Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study. Abstract. ASH 817
74. P Wijermans M Lübbert G Verhoef A Bosly C Ravoet M Andre 2000 Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients J Clin Oncol 18 5 956 962
75. M Lübbert P Wijermans R Kunzmann G Verhoef A Bosly C Ravoet 2001 Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine A Br J Haematol 4 2 349
76. H Kantarjian JP Issa CS Rosenfeld JM Bennett M Albitar J DiPersio 2006 Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 8 1794 1803
77. A Kuendgen N Gattermann 2007 Valproic acid for the treatment of myeloid malignancies Cancer 110 5 943 954
78. BR Greenberg RD Reynolds CB Charron KM Squillace LS Lessin DC Case Jr 1993 Treatment of myelodysplastic syndromes with daily oral idarubicin. A phase I-II study Cancer 71 6 1989 1199
79. E Omoto S Deguchi S Takaba K Kojima T Yano Y Katayama 1996 Low-dose melphalan for treatment of high-risk myelodysplastic syndromes Leukemia 10 4 609 614
80. E Wattel A Guerci B Hecquet T Economopoulos A Copplestone B Mahé 1996 A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group Blood 88 7 2480 2487
81. HH Gerhartz R Marcus A Delmer H Zwierzina S Suciu M Dardenne 1994 A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group Leukemia 8 1 16 23
82. W Verbeek A Ganser 2001 Evolving treatment options of myelodysplastic syndromes Ann Hematol 80 499 509
83. WK Hofmann G Heil C Zander 2004 Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia Ann Hematol 83 498 503
84. S Knipp B Hildebrand A Kündgen A Giagounidis G Kobbe R Haas 2007 Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes Cancer 110 2 345 352
85. W Ingram ZY Lim GJ Mufti 2007 Allogeneic transplantation for myelodysplastic syndrome (MDS) Blood Reviews 21 61 71
86. J Stary F Locatelli CM Niemeyer 2005 Stem cell transplantation for aplastic anemia and myelodysplastic syndrome Bone Marrow Transplantation 35 S13 S16
87. HJ Deeg 2006 Transplant strategies for patients with myelodysplastic syndromes Curr Opin Hematol 13 61 66
88. H Gratwohl Baldomero K Frauendorfer A Urbano-Ispizua D Niederwieser 2007 Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation; focus on increasing use of unrelated donors Bone Marrow Transplantation 39 71 87
89. CS Cutler SJ Lee P Greenberg HJ Deeg WS Pérez C Anasetti 2004 A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome Blood 104 579 585
90. E Estey M de Lima R Tibes S Pierce H Kantarjian R Champlin 2007 Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) Blood 109 1395 1400
91. LR Silverman 2006 Before and after transplantation: treatment strategies for patients with myelodysplastic syndromes Blood and Marrow Transplantation 16 4 12
92. L Burroughs R Storb 2004 Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease Curr Opin Hematol 12 45 54
93. R Martino S Iacobelli R Brand T Jansen A van Biezen J Finke 2006 Myelodysplastic Syndrome subcommittee of the Chronic Leukemia Working Party of the European Blood and Marrow Transplantation Group. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes Blood 108 3 836 846
94. N Kröger R Brand A van Biezen JY Cahn S Slavin D Blaise 2006 Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome Bone Marrow Transplantation 37 183 189
95. JW Vardiman NL Harris RD Brunning 2002 The World Health Organization (WHO) classification of the myeloid neoplasms Blood 100 2292 2302
96. J Pedersen-Bjergaard SO Larsen 1982 Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease N Engl J Med 307 965 971
97. SM Smith MM Le Beau D Huo T Karrison RM Sobecks J Anastasi 2003 Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series Blood 102 43 52
98. N Mauritzson M Albin L Rylander R Billström T Ahlgren Z Mikoczy 2002 Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001 Leukemia 16 2366 2378
99. ML Amigo MC del Canizo A Rios MA Garcia MD Caballero A Martin 1999 Diagnosis of secondary myelodysplastic syndromes (MDS) following autologous transplantation should not be based only on morphologic criteria used for diagnosis of de novo MDS Bone Marrow Transplant 23 997 1002
100. RA Larson M Wernli MM Le Beau KM Daly LH Pape JD Rowley 1988 Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine Blood 72 1333 1339
101. H Kantarjian M Beran J Cortes S O'Brian F Giles S Pierce 2006 Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome Cancer 106 1099 1109
102. KK Ballen DG Gilliland EC Guinan C-C Hsieh SK Parsons IJ Rimm 1997 Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia Bone Marrow Transplant 20 737 743
103. RP Witherspoon HJ Deeg B Storer C Anasetti R Storb FR Appelbaum 2001 Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia J Clin Oncol 19 2134 2141
104. I Yakoub-Agha P de La Salmoniere P Ribaud L Sutton E Wattel M Kuentz 2000 Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients - report of the French society of bone marrow transplantation J Clin Oncol 18 963 971
105. P Woodard R Barfield G Hale E Horwitz W Leung R Ribeiro 2006 Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome Pediatr Blood Cancer 47 931 935
106. C Chang BE Storer BL Scott EM Bryant HM Shulman ME Flowers 2007 Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedant hematologic disorders Blood 110 1379 1387
107. N Kröger R Brand A van Biezen J-Y Cahn S Slavin D Blaise 2006 Autologous stem cell transplantation for therapy-related myeloid leukemia and myelodysplastic syndrome Bone Marow Transplant 37 183 189
108. H Sill W Zinke-Cerwenka A Berghold 2007 Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome Bone Marow Transplant 39 509 author reply 509-510
109. M Melchert C Williams A List 2007 Remitting activity of lenalidomide in treatment-induced myelodysplastic syndrome Leukemia 21 1576 1578
110. H Sill 2008 Susceptibility to Therapy-related Myelodysplastic Syndromes and Acute Myeloid Leukemia Clin Adv Hematol Oncol 6 164 165
111. A Zebisch PB Staber A Delavar C Bodner K Hiden K Fischereder 2006 Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia Cancer Res 66 3401 3408
112. BD Cheson PL Greenberg JM Bennett B Lowenberg PW Wijermans SD Nimer A Pinto M Beran TM de Witte RM Stone M Mittelman GF Sanz SD Gore CA Schiffer H Kantarjian 2006 Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia Blood 108 2 419 425 Epub 2006 Apr 11